Telegram游戏破解:TNB offers ‘Sinaran Merdeka’ incentive

Telegram游戏破解是一个Telegram群组分享平台。Telegram游戏破解包括Telegram群成员导出、telegram群组索引、Telegram群组导航、新加坡telegram群组、telegram中文群组、telegram群组(其他)、Telegram 美国 群组、telegram群组爬虫、电报群 科学上网、小飞机 怎么 加 群、tg群等内容。Telegram游戏破解为广大电报用户提供各种电报群组/电报频道/电报机器人导航服务。

In conjunction with this year’s 65th National Day, TNB returns with Sinaran Merdeka incentive to encourage commercial customers to light up their buildings and surrounding areas with decorative lighting.

KUALA LUMPUR: Tenaga Nasional Bhd (TNB) is offering ‘Sinaran Merdeka’ incentive to encourage commercial customers to light up their buildings and surrounding areas with decorative lighting, in conjunction with this year’s 65th National Day.

The utility giant, in a statement, said customers will enjoy the ‘Sinaran Merdeka’ incentive for a period of two months, from Aug 1 to Sept 30 2022.

“The incentive rate of 20.8 sen/kWh offered is lower than the existing rate. The incentive is also given for any amount of increase in electricity consumption exceeding the average consumption in three months from May, June, and July 2022,” TNB said.

According to TNB, the annual incentive, which started in 2000, is offered to all customers under commercial tariffs that include skyscrapers, office buildings, commercial complexes, shopping complexes, hotels and gas stations.




Eligible customers are those under the commercial tariffs who have received electricity before Aug 1 and obtained at least one actual bill between May to July 2022. This special incentive will be reflected in October 2022 bill, denoted as ‘Carnival Discount’.

Last year, TNB received a total of 3,096 applications for Sinaran Merdeka Incentive, with 62% or 1,910 customers identified as eligible.

Application for this promotion starts on Aug 1 and until Sept 15. Customers can apply online through or at the nearest Kedai Tenaga.

For more information, contact TNB CareLine at 1-300-88-5454, visit or email:


  • 评论列表:
  •  泰达币交易所官网(
     发布于 2022-09-14 00:14:23  回复
  • 6月23日,由复星凯特生产的CAR-T细胞治疗产物益基利仑赛注射液(又称阿基仑赛注射液,商品名:奕凯达)正式获批上市。该产物将用于治疗二线或以上系统性治疗后复发或难治性大 B 细胞淋巴瘤成人患者。超爱,是我想要的